Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Incannex Healthcare Inc. - Common Stock (NQ: IXHL ) 1.780 +0.110 (+6.59%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 20, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Incannex Healthcare Inc. - Common Stock < Previous 1 2 3 4 5 6 7 Next > FDA Clears Incannex To Proceed With Phase 2 Psilocybin-Assisted Therapy Trial For Anxiety August 05, 2024 FDA approves Incannex's Phase 2 trial for psilocybin-assisted psychotherapy in treating generalized anxiety disorder, following a successful review of the IND application. Via Benzinga Exposures Product Safety Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday July 01, 2024 We have the biggest pre-market stock movers that investors are going to want to start the trading week with on Monday morning! Via InvestorPlace Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday June 27, 2024 Pre-market stock movers are worth checking out on Thursday as we dig into all of the biggest news moving shares this morning! Via InvestorPlace FDA Experts Weigh In On Incannex's CannQuit-O With Feedback On CBD As Treatment For Opioid Use Disorder May 07, 2024 Incannex Healthcare Inc., a cannabinoid and psychedelic medicine biotechnology company, announced the successful completion of a pre-investigational new drug meeting with the U.S. Food and Drug... Via Benzinga Exposures Product Safety Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More April 17, 2024 Via Benzinga Largest Psychedelic Drug Stocks Up Another 10% Last Week; Now Up 54% YTD April 12, 2024 The 5 constituents in the Psychedelic Compound-Based Drug Stocks Index were up 10.0%, on average, last week and are now up 53.9% YTD. Via Talk Markets March Recap: Largest Psychedelic Drug Stocks Up Another 5% March 30, 2024 The 5 constituents in the munKNEE Psychedelic Compound-Based Drug Stocks Index were UP 5.4%, on average, in March and are now UP 39.9% YTD. Via Talk Markets Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence March 29, 2024 Via Benzinga Psychedelic-Assisted Therapy Advancements Create A New Horizon For Mental Health In Colorado March 22, 2024 Psilocybin-assisted therapy shows promise in treating GAD. Denver trains first responders in psychedelic crisis intervention. Heroic Hearts Project supports veterans with PTSD through legal psychedelic... Via Benzinga Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More March 20, 2024 Via Benzinga Topics Economy Exposures Interest Rates Psychedelic Compound-Based Drug Stock, Mind Medicine, Up 56% Last Week March 11, 2024 The FDA has granted breakthrough designation to Mind Medicine's program for the treatment of generalized anxiety disorder. Via Talk Markets Exposures Product Safety Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More March 04, 2024 Via Benzinga Largest Psychedelic Compound-Based Drug Stocks Up 15% In February; Now Up 33% YTD March 01, 2024 The Psychedelic Compound-Based Drug Stocks Index was up 15.0% in February led by Incannex Healthcare which was up 55.1%. Via Talk Markets Psilocybin-Assisted Therapy Achieves Positive Clinical Trial Results For Treating Generalized Anxiety February 28, 2024 Via Benzinga What's Going On With Incannex Stock? February 28, 2024 Incannex said that its Phase 2 Psi-GAD1 clinical trial of psilocybin in generalized anxiety disorder met its primary endpoint of demonstrating a large clinical effect in the psilocybin treatment group... Via Benzinga How I Swing Trade Via Strength With Recent Examples February 25, 2024 In this video, I explain how I avoid major losses, keep my losses small, and maximize gains. I also provide some recent trades as examples. Via Talk Markets Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session February 28, 2024 Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results. Via Benzinga Psychedelic Stocks Index Popped 8% Last Week, Led By Incannex February 18, 2024 IXHL 's increase was based on the successful completion of an Investigational New Drug meeting with the U.S. Food and Drug Administration regarding the development of CannQuit-N for tobacco smoking... Via Talk Markets Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More February 15, 2024 Via Benzinga Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More February 15, 2024 Via Benzinga 5 Largest Psychedelic Compound-Based Drug Stocks Up 17% Last Week January 30, 2024 The 5 constituents in the Psychedelic Drug Stocks Index jumped 16.7%, on average, last week and are now up 11.7% MTD. Via Talk Markets Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More January 27, 2024 New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian... Via Benzinga Podcast: International Cannabis And Psychedelics Co. Is Working 'Hand In Hand' With FDA To Forge New Therapy Frontiers January 25, 2024 Via Benzinga Topics Cannabis Exposures Cannabis Product Safety 5 Largest Psychedelic Drug Stocks Advanced Slightly Last Week January 13, 2024 The munKNEE Psychedelic Drug Stocks Index went up 2.3% last week and is now up 1.8% MTD. Via Talk Markets Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More January 12, 2024 Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD Via Benzinga Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More January 07, 2024 Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury Via Benzinga Global Mofy Metaverse Reports Follow-on Offering, Joins Lyft, Coinbase Global And Other Big Stocks Moving Lower On Friday December 29, 2023 U.S. stocks traded mixed, with the Nasdaq Composite falling around 0.3% on Friday. Shares of Global Mofy Metaverse Limited (NASDAQ: GMM) shares fell sharply during Friday’s session after the company... Via Benzinga Topics Stocks Exposures US Equities Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More December 27, 2023 President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also... Via Benzinga Psychedelic Drug Stocks Index Up In December; Down YTD December 27, 2023 The constituents in the Index are up 9.1% MTD, on average, are down 29.2% YTD, on average, and are now down 85.9% from their highs in 2021. Via Talk Markets Incannex Healthcare To Open First Psychedelic-Assisted Therapy Clinic In Australia December 22, 2023 Melbourne will soon open Clarion Clinics’ first exclusively dedicated facility to provide psychedelic-assisted therapies legalized in Australia. Via Benzinga < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.